N6-methyladenosine (m6A) in cancer stem cell: From molecular mechanisms to therapeutic implications
The emergence of drug resistance and metastasis has long been a difficult problem for cancer treatment. Recent studies have shown that cancer stem cell populations are key factors in the regulation of cancer aggressiveness, relapse and drug resistance. Cancer stem cell (CSC) populations are highly p...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-07-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332223006364 |
| _version_ | 1797822162070929408 |
|---|---|
| author | Liming Wang Yuanxin Tang |
| author_facet | Liming Wang Yuanxin Tang |
| author_sort | Liming Wang |
| collection | DOAJ |
| description | The emergence of drug resistance and metastasis has long been a difficult problem for cancer treatment. Recent studies have shown that cancer stem cell populations are key factors in the regulation of cancer aggressiveness, relapse and drug resistance. Cancer stem cell (CSC) populations are highly plastic and self-renewing, giving them unique metabolic, metastatic, and chemotherapy resistance properties. N6-methyladenosine (m6A) is the most abundant internal modification of mRNA and is involved in a variety of cell growth and development processes, including RNA transcription, alternative splicing, degradation, and translation. It has also been linked to the development of various cancers. At present, the important role of m6A in tumour progression is gradually attracting attention, especially in the tumour stemness regulation process. Abnormal m6A modifications regulate tumour metastasis, recurrence and drug resistance. This paper aims to explore the regulatory mechanism of m6A in CSCs and clinical therapy, clarify its regulatory network, and provide theoretical guidance for the development of clinical targets and improvement of therapeutic effects. |
| first_indexed | 2024-03-13T10:03:52Z |
| format | Article |
| id | doaj.art-f4cebe7de99e460c97c5ac3c73d85cff |
| institution | Directory Open Access Journal |
| issn | 0753-3322 |
| language | English |
| last_indexed | 2024-03-13T10:03:52Z |
| publishDate | 2023-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedicine & Pharmacotherapy |
| spelling | doaj.art-f4cebe7de99e460c97c5ac3c73d85cff2023-05-23T04:21:16ZengElsevierBiomedicine & Pharmacotherapy0753-33222023-07-01163114846N6-methyladenosine (m6A) in cancer stem cell: From molecular mechanisms to therapeutic implicationsLiming Wang0Yuanxin Tang1Department of General Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, P.R. ChinaCorresponding author.; Department of General Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, P.R. ChinaThe emergence of drug resistance and metastasis has long been a difficult problem for cancer treatment. Recent studies have shown that cancer stem cell populations are key factors in the regulation of cancer aggressiveness, relapse and drug resistance. Cancer stem cell (CSC) populations are highly plastic and self-renewing, giving them unique metabolic, metastatic, and chemotherapy resistance properties. N6-methyladenosine (m6A) is the most abundant internal modification of mRNA and is involved in a variety of cell growth and development processes, including RNA transcription, alternative splicing, degradation, and translation. It has also been linked to the development of various cancers. At present, the important role of m6A in tumour progression is gradually attracting attention, especially in the tumour stemness regulation process. Abnormal m6A modifications regulate tumour metastasis, recurrence and drug resistance. This paper aims to explore the regulatory mechanism of m6A in CSCs and clinical therapy, clarify its regulatory network, and provide theoretical guidance for the development of clinical targets and improvement of therapeutic effects.http://www.sciencedirect.com/science/article/pii/S0753332223006364Cancer stem cellN6-methyladenosine (m6A)Clinical treatmentFTOMETTL3 |
| spellingShingle | Liming Wang Yuanxin Tang N6-methyladenosine (m6A) in cancer stem cell: From molecular mechanisms to therapeutic implications Biomedicine & Pharmacotherapy Cancer stem cell N6-methyladenosine (m6A) Clinical treatment FTO METTL3 |
| title | N6-methyladenosine (m6A) in cancer stem cell: From molecular mechanisms to therapeutic implications |
| title_full | N6-methyladenosine (m6A) in cancer stem cell: From molecular mechanisms to therapeutic implications |
| title_fullStr | N6-methyladenosine (m6A) in cancer stem cell: From molecular mechanisms to therapeutic implications |
| title_full_unstemmed | N6-methyladenosine (m6A) in cancer stem cell: From molecular mechanisms to therapeutic implications |
| title_short | N6-methyladenosine (m6A) in cancer stem cell: From molecular mechanisms to therapeutic implications |
| title_sort | n6 methyladenosine m6a in cancer stem cell from molecular mechanisms to therapeutic implications |
| topic | Cancer stem cell N6-methyladenosine (m6A) Clinical treatment FTO METTL3 |
| url | http://www.sciencedirect.com/science/article/pii/S0753332223006364 |
| work_keys_str_mv | AT limingwang n6methyladenosinem6aincancerstemcellfrommolecularmechanismstotherapeuticimplications AT yuanxintang n6methyladenosinem6aincancerstemcellfrommolecularmechanismstotherapeuticimplications |